EP Patent

EP3551187B1 — Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol

Assigned to Boehringer Ingelheim International GmbH · Expires 2021-02-17 · 5y expired

What this patent protects

Patent listed against Jascayd.

Drugs covered by this patent

Patent Metadata

Patent number
EP3551187B1
Jurisdiction
EP
Classification
—
Expires
2021-02-17
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.